View Zepbound Details Mounjaro (tirzepatide) Dual-action control originally approved for Type 2 Diabetes
"We welcome expanded treatment options to support Canadians living with obesity." About Wegovy Health Canada approved Wegovy in 2021 as a once-weekly treatment for Canadians living with obesity, supported by the efficacy and safety data from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program
Drugs in context , 12 , 2023-6-1
Market analysis shows the global obesity GLP-1 market was valued at about USD 8.21 billion in 2025 and is expected to reach roughly USD 66.57 billion by 2035, expanding at a CAGR of about 23% due to rising obesity rates and strong clinical effectiveness of GLP-1 drugs
Careful follow-up for weight in pediatric patients ages 6 to 12 years who received VYVANSE over 12 months suggests that consistently medicated pediatric patients (i.e., treatment for 7 days per week throughout the year) have a slowing in growth rate, measured by body weight as demonstrated by an age- and sex-normalized mean change from baseline in percentile, of -13.4 over 1 year (average percentiles at baseline and 12 months were 60.9 and 47.2, respectively)
